Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Antiandrogen agents, PARP inhibitors, and prostate-specific membrane antigen-directed therapy have broadened the armamentarium in prostate cancer.

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.